17 Feb 2022 , 02:50 PM
In its latest Sectoral Strategy Report, ICRA has analysed the cumulative positive impact of the PLI scheme. It says that the sectors have been strategically selected by the Government, considering India’s surging demand (solar, semiconductors/electronics, automobiles etc.), and are critical to develop manufacturing capabilities (semiconductors, telecom gears, medical devices).
The scheme, spread across 14 sectors, can enhance India’s annual manufacturing capex by ~15 to 20% from FY23. However, potential challenges are expected from execution delays, increasing funding costs, availability of requisite infrastructure and delays in approvals,” Mr Rohit said.
Of the total manufacturing outlay, about ~80% is concentrated towards electronics, auto, solar panel manufacturing of which the focus towards semiconductors/electronics value chain is ~50% of outlay. Incentives are based on incremental production/revenue, spread over five years on an average across sectors. Some schemes are also linked to capital investments.
~50% OF THE OUTLAY CONCENTRATED TOWARDS THE ELECTRONICS VALUE CHAIN
Coming to specific sector outlays, PLI for semiconductor manufacturing is at Rs760 billion, and aims to make India one of the leading manufacturers globally of this critical component. Shortage of semiconductor chips is leading to major production delays in autos and electronics globally as they are critical components used in automobiles and electronic items such as mobile phones/ smartphones, televisions, washing machines, refrigerators etc. Given the fact that India’s dependence on semiconductors is expected to increase substantially, this PLI scheme is critical. For automobiles, the cabinet has approved Rs259 billion (out of Rs570 billion earmarked) and bids for the same have been closed. Additionally, the PLI for ACC battery is estimated at Rs181 billion with incremental production estimated at 50 GW.
The PLI allocation of solar PV modules has been increased to Rs240 billion (from Rs45 billion). Considering India’s ambitious plans to expand solar generation, this scheme may continue to attract addition allocation every year. For pharma, an outlay of Rs249 billion is further bifurcated into Rs69 billion towards KSMs/DIs and APIs, Rs150 billion for pharma sector and balance Rs30 billion towards bulk drug parks. This apart, in telecom, Rs122 billion has been allocated, food processing has been given an outlay of Rs109 billion, textile exports of Rs107 billion, specialty steel Rs63 billion and drone segment Rs1.2 billion.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.